Should There Be a Quota for Minority Populations in Drug Trials?
Amidst a wave of new cancer therapies, minority patients are often underrepresented in clinical trials, causing them to miss out on experimental treatments and suffer unanticipated side effects when drugs go to market. The FDA has avoided passing requirements for minority participation in clinical trials, citing a lack of regulatory authority. Without these mandates, pharmaceutical companies have not been compelled to diversify trials.
Minority patients are often underrepresented in cancer drug trials, causing them to miss out on treatments and suffer unanticipated side effects when drugs are approved. Are you for or against a mandatory quota for minority populations in drug trials?
Last Answered: Over a month ago